Bray Capital Advisors lessened its holdings in CVS Health (NYSE:CVS) by 69.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,754 shares of the pharmacy operator’s stock after selling 19,975 shares during the quarter. Bray Capital Advisors’ holdings in CVS Health were worth $635,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. FIL Ltd boosted its holdings in shares of CVS Health by 13.8% in the 2nd quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock valued at $41,424,000 after purchasing an additional 62,318 shares during the last quarter. ETRADE Capital Management LLC lifted its holdings in CVS Health by 3.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 55,653 shares of the pharmacy operator’s stock worth $4,478,000 after buying an additional 1,979 shares in the last quarter. Ally Financial Inc. lifted its holdings in CVS Health by 20.0% in the 2nd quarter. Ally Financial Inc. now owns 90,000 shares of the pharmacy operator’s stock worth $7,241,000 after buying an additional 15,000 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of CVS Health by 17.9% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 77,859 shares of the pharmacy operator’s stock worth $5,645,000 after purchasing an additional 11,800 shares during the last quarter. Finally, Checchi Capital Advisers LLC increased its position in shares of CVS Health by 14.5% in the 4th quarter. Checchi Capital Advisers LLC now owns 9,063 shares of the pharmacy operator’s stock worth $657,000 after purchasing an additional 1,150 shares during the last quarter. 83.97% of the stock is owned by institutional investors.
In other CVS Health news, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares in the company, valued at approximately $4,622,714.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.61% of the stock is currently owned by corporate insiders.
CVS stock traded up $0.93 during midday trading on Thursday, reaching $64.00. 5,496,728 shares of the company were exchanged, compared to its average volume of 8,572,738. The stock has a market cap of $64,899.61, a price-to-earnings ratio of 10.85, a price-to-earnings-growth ratio of 1.06 and a beta of 1.05. CVS Health has a one year low of $60.14 and a one year high of $84.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52.
CVS Health (NYSE:CVS) last issued its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm had revenue of $48.39 billion during the quarter, compared to the consensus estimate of $47.54 billion. During the same quarter in the previous year, the firm earned $1.71 earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis. research analysts anticipate that CVS Health will post 6.31 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 3rd. Shareholders of record on Monday, April 23rd will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.13%. The ex-dividend date of this dividend is Friday, April 20th. CVS Health’s payout ratio is 33.90%.
CVS has been the subject of a number of recent research reports. Robert W. Baird lowered their price objective on shares of CVS Health from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, February 9th. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Vetr lowered shares of CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price for the company. in a research note on Thursday, January 4th. UBS upgraded shares of CVS Health from an “outperform” rating to a “strong-buy” rating in a report on Thursday, January 4th. Finally, Needham & Company LLC upgraded shares of CVS Health from a “buy” rating to a “strong-buy” rating and upped their price objective for the company from $88.00 to $100.00 in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $86.65.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://macondaily.com/2018/04/12/bray-capital-advisors-lowers-stake-in-cvs-health-corp-cvs-updated-updated-updated.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.